Why the fastest-growing benefit category has no operating layer, what that costs, and how the specialty management model that transformed imaging, oncology, and musculoskeletal care applies to the full women's health continuum.
Women's health specialty spend is growing faster than any other benefit category. The management infrastructure for it is twenty years behind imaging, oncology, and cardiac care. No delegated specialty manager governs fertility, maternity, autoimmune, GI, and Rx as an integrated book. The market has instead produced condition-specific point solutions that serve members but do not govern cost, quality, or clinical accountability at the population level. This paper traces the precedent set by delegated specialty management in other clinical domains, measures the economic and clinical cost of fragmentation in women's health, and proposes a governance-first model that evolves into hybrid governance and selective service delivery as the data matures. It draws on publicly reported financials, peer-reviewed literature, federal datasets, and the operating history of the companies that built the specialty management category.
The idea that a health plan would delegate clinical management of an entire specialty domain to an external company was controversial in 1995. By 2010, it was standard operating procedure.
National Imaging Associates, founded in 1995, demonstrated that a focused clinical team applying evidence-based criteria to advanced imaging authorizations could reduce unnecessary utilization by 15-25% without degrading clinical outcomes.1 NIA managed imaging benefits for 35 million lives by the time Magellan acquired it. CareCore National, founded a year earlier, built the same model independently and eventually merged with MedSolutions to form eviCore Healthcare, which now manages specialty utilization for over 100 million covered lives across 100+ health plans.2
The pattern repeated. New Century Health applied delegated governance to oncology treatment pathways starting in 2012, managing evidence-based protocol adherence and provider performance for 3.5 million oncology and cardiology lives before Evolent acquired them for up to $217 million in cash, stock, and earn-out.3 AIM Specialty Health built the same model in imaging and was acquired by a national payer in 2014 to bring the capability in-house rather than continue paying PMPM fees to an external vendor.4
The economic logic has not changed across two decades of transactions. The delegated specialty manager possesses deeper clinical subspecialty expertise than the health plan can recruit internally, applies it at lower cost through scale and focus, and generates savings that exceed the PMPM fee by a factor of 2 to 5. The payer retains medical policy authority, claims adjudication, and member relationships. The delegator operates the clinical engine.
| Company | Domain | Acquirer | Price | Revenue Multiple |
|---|---|---|---|---|
| NIA (Magellan Specialty Health) | Imaging | Evolent Health (2022) | ~$800M | 3-4x |
| eviCore Healthcare | Multi-specialty UM | Express Scripts (2017) | $3.6B | 6-7x |
| New Century Health | Oncology/Cardiology | Evolent Health (2020) | up to $217M | 5-6x |
| AIM Specialty Health | Imaging | National payer (2014) | Undisclosed | ~4-5x est. |
| Accordant Health | Rare/Chronic Disease | CVS/Caremark (2004) | $165M | ~4x |
Every successful delegated specialty manager shared one trait: they were more clinically credible in their specific domain than the generalist health plan could be internally. That domain expertise was the moat. The business model was a PMPM fee, typically $0.50-$3.00 depending on scope, with performance guarantees and, in many cases, shared savings components that aligned the delegator's economics with the payer's cost reduction goals.5
Every 5-10 years, a new clinical domain becomes the target. The 1990s were imaging. The 2000s added cardiac and musculoskeletal. The 2010s added oncology and genetic testing. Women's health is the next domain for the same structural reasons: concentrated cost, measurable clinical variation, and internal payer infrastructure that is not adequate to the task.
The United States spends more per capita on maternal care than any peer nation and produces worse outcomes than all of them.
Maternal mortality stands at 17.9 deaths per 100,000 live births, down from a peak of 32.9 during 2021 but still far above peer nations.6 Black women die at 3.2 times the rate of white women, a disparity that has widened, not narrowed.7 The CDC's Maternal Mortality Review Committees examined these deaths and concluded that 84% were preventable.8 Not theoretically preventable. Preventable with interventions that already exist and were not deployed.
The C-section rate sits at 32.5%, a decade high and still trending upward, more than double the World Health Organization's recommended threshold of 10-15%.9 Variation across hospitals ranges from 12% to over 60%, which is not a clinical variation. It is a governance failure. Every unnecessary C-section adds $15,000-20,000 in surgical cost, extends recovery by weeks, increases complication risk for subsequent pregnancies, and feeds the downstream utilization cycle.
The cost concentration extends well beyond maternity. Autoimmune conditions affect women at a 4:1 ratio to men, representing 80% of the autoimmune disease population.11 The average time to diagnosis is 4.6 years.12 During those years, patients cycle through specialists, accumulate imaging and lab costs, fill prescriptions that treat symptoms rather than root causes, and deteriorate clinically. Autoimmune flare management alone represents projected savings of $3.2 million per 100,000 covered lives annually, based on flare reduction and biologic management modeling.
GI disorders cost the US healthcare system $111.8 billion annually.13 Women have 41% more GI-related emergency department visits than men.14 IBS is the most common misdiagnosis for endometriosis patients, with diagnostic delays averaging 7-10 years before the correct diagnosis is reached.15 This is not a diagnostic challenge. It is a system design failure. The GI specialist does not know about the gynecological history. The OB/GYN does not know about the GI workup. Nobody owns the longitudinal picture.
A woman managing fertility treatment, pregnancy, a postpartum autoimmune flare, and GI symptoms will interact with four or five separate vendor programs if her employer or plan has them at all. More likely, she has one (fertility, through Progyny or Maven) and the rest is unmanaged fee-for-service.
No single entity owns the cross-condition clinical picture. Nobody is governing Rx spend across fertility medications, prenatal care, autoimmune biologics, and GI treatments. Nobody is steering to high-performing OB/GYN providers based on C-section rates, NICU transfer rates, or complication metrics. Nobody is managing the handoff from reproductive endocrinologist to obstetrician to maternal-fetal medicine specialist to postpartum care to the rheumatologist who should be monitoring the autoimmune flare that pregnancy triggers in 30-40% of susceptible women.
This fragmentation has a name in every other specialty domain. In imaging, it was "unmanaged utilization" until NIA and CareCore built governance around it. In oncology, it was "clinical variation" until New Century Health built pathway management around it. In women's health, it is still called "normal."
The market produced $5 billion in aggregate valuation across companies that serve pieces of the problem. None of them governs the whole.
Maven raised capital at a $1.7 billion valuation and reports approximately $268 million in annual recurring revenue across 28 million covered lives.16 It is a virtual care and navigation platform. Members use it to connect with providers, receive coaching, and navigate fertility and maternity benefits. Maven is a consumer product. It acquires members, delivers services, and measures engagement. It does not manage the payer's women's health book. It does not govern provider performance across a delivery network. It does not manage cross-condition Rx utilization.
Maven's primary buyer is the employer, not the health plan. When Maven sells through a health plan, the plan is a distribution channel, not the economic buyer. This distinction matters because it means Maven's economics depend on member engagement rates, which in digital health typically run 3-8% of the eligible population.17 Governance economics depend on covered lives, not engaged members. Every woman on the book generates PMPM revenue whether she ever opens an app or not.
Progyny is the closest thing to a governance model in women's health, and it covers fertility alone. The company generated $1.29 billion in revenue in 2024 through its Smart Cycle benefit structure, managed provider network, and fertility Rx management, serving 7.6 million covered members through 600+ employer clients.18 Progyny manages the fertility benefit the way a specialty manager should: network tiering based on outcomes (live birth rates), bundled pricing through Smart Cycles, and integrated pharmacy. It is proof that governance-grade management works in women's health. It is also proof that the market has only applied it to one module.
In April 2026, Progyny launched "Progyny Select," a fully insured supplemental plan distributed through brokers and health plan partners, targeting employers under 1,000 lives.19 This is the first time Progyny has used health plans as a true distribution channel. Implementation begins in the 2027 plan year. The fact that it took the market's most successful women's health specialty company 12 years to move beyond employers tells you something about how difficult the payer channel is for single-module solutions.
Pomelo raised $92 million in a Series C at a $1.7 billion valuation in 2025 to manage maternity outcomes.20 Unlike Maven, Pomelo sells primarily to health plans and Medicaid MCOs. Unlike Progyny, Pomelo delivers clinical care directly: virtual OB visits, midwifery services, doula support (through its acquisition of the Doula Network). Pomelo covers 25 million lives across 46 states through value-based contracts tied to C-section rates and preterm birth rates.
Pomelo is a maternity service delivery vendor with performance wrapping. It does not manage fertility. It does not manage autoimmune conditions. It does not govern specialty Rx across conditions. It does not manage provider network performance. It delivers care to the member. That is a different product than managing the book.
| Company | Model | Fertility | Maternity | Autoimmune | GI | Rx Mgmt |
|---|---|---|---|---|---|---|
| Maven | Virtual care / navigation | ✓ | ✓ | — | — | — |
| Progyny | Fertility benefit mgmt | ✓ | — | — | — | ✓ |
| Pomelo | Virtual maternity care | — | ✓ | — | — | — |
| Visana | Virtual medical home | ✓ | ✓ | — | — | — |
| Wildflower | Digital engagement | — | ✓ | — | — | — |
| eviCore | Delegated UM (multi-specialty) | — | — | — | — | — |
| Evolent / NCH | Delegated specialty governance | — | — | — | — | — |
The consumer-facing companies (Maven, Pomelo, Visana) built apps. The specialty management companies (eviCore, Evolent) built governance engines for other domains and have not applied them to women's health. The space between those two categories is empty. Nobody manages fertility and maternity and autoimmune and GI and Rx as a single integrated specialty book under a governance framework. That is the gap.
Every major national payer runs an internal maternity management program. None of them works well enough to eliminate the need for external governance.
UnitedHealthcare operates "Healthy Pregnancy" through Optum: telephonic nurse outreach for high-risk pregnancies, digital content for standard-risk, and NICU care coordination. Humana runs "HumanaBeginnings." Cigna runs "Healthy Pregnancies, Healthy Babies." Other national payers run similar legacy programs, some dating to the mid-2000s, built around nurse case management, incentive-based member engagement, and high-risk care plans.21
These programs share structural limitations that no amount of internal investment has resolved:
The procurement fragmentation inside large payers is both the cause of the gap and the opportunity for an external company to fill it. When no internal department owns women's health end-to-end, no internal champion has been empowered to solve it. The person who consolidates those silos from the outside creates value that no internal reorganization has produced.
There are three ways to enter this market. Each has a different capital requirement, political profile, and path to the buyer's signature.
You deliver care to members. Virtual visits, navigation, coaching. This requires clinicians on payroll, a technology platform, state-by-state licensure, malpractice coverage, NCQA accreditation, and a member engagement engine. Maven has raised over $300 million to build this. Pomelo has raised $171 million. These are not bootstrappable businesses. And they face the highest political resistance inside large health plans because they directly duplicate what internal care management teams already do. Every maternity navigator you deploy is a line item that threatens the medical director's existing headcount.
You manage the book. Clinical pathway enforcement, provider performance scoring, Rx utilization management, analytics. You never talk to the member. You sit between the payer and the delivery system and enforce standards. This requires a fraction of the capital: $1.2-3 million to launch. It is bootstrappable. And it presents lower political risk because you are not threatening internal clinical teams. You are giving them better data and more targeted interventions. The medical director does not lose staff. The medical director gains an operating system.
Governance generates PMPM revenue on all covered lives, not just engaged members. A 100,000-life book at $1.50 PMPM is $1.8 million annually regardless of how many members open an app. This is the economic structure that made eviCore a $3.6 billion acquisition and NIA a multi-decade franchise.
You govern the book AND deliver selective services where the payer has clear gaps. This is the model that produces the strongest moat, the highest switching costs, and the largest revenue per covered life. It is also where the market needs to go. The question is when to introduce the service delivery component.
The answer is: after the data tells you where.
This is the operating thesis. Governance first. Hybrid second. The transition is not a strategic pivot. It is a data-driven expansion funded by the governance foundation.
Land the first contracts on a governance-only basis. Employers and TPAs first (single procurement door, 6-month sales cycles), regional plans second (12-month sales cycles). The product is pathway management, provider scoring, Rx utilization oversight, and actuarial reporting. PMPM fee of $1.50-$3.00 across all female lives.
Capital requirement: $1.2-3 million. Bootstrappable. No clinical staff delivering care. No member-facing technology. The buyer is the actuary and the VP of medical management.
What you learn: Where the payer's internal teams are falling short. Which providers have C-section rates above 40%. Which pregnancies are being identified as high-risk too late. Where NICU admissions could have been prevented. Where Rx spend is leaking across conditions. The governance layer produces the diagnostic that justifies Phase 2.
After 6-12 months of governing the book, you have data the payer has never seen before. Cross-condition utilization patterns. Provider performance at the individual level. NICU avoidance opportunities that were missed. Postpartum readmission patterns correlated with behavioral health gaps. Autoimmune flare rates post-pregnancy.
You present this data to the CMO and say: your high-risk OB readmission rate is 18%. Your NICU avoidance capture rate is 40% of identifiable cases. You are leaving $X million on the table. We can deploy a targeted clinical team to close these specific gaps.
This is an upsell, not a new sale. The data makes the case. The internal medical director does not feel threatened because you are offering to help with cases they already know they are losing. The service component becomes political lubricant for deeper governance authority.
You are now governing the book AND delivering targeted high-risk care management, NICU avoidance outreach, postpartum transition support, and complex case navigation for the cases that fall between internal silos. Your PMPM rises from $1.50 to $3.00-$4.00. Your margin structure blends high-margin governance with moderate-margin service delivery.
The switching cost is now substantial. The payer would need to replace both their operating layer and their gap-filling clinical programs simultaneously. They would lose the provider performance data, the pathway compliance benchmarks, and the cross-condition analytics that no other entity can replicate from a standing start.
Staff model at this stage: 3-5 medical directors, 10-20 specialized care managers (high-risk OB, NICU avoidance, Rx management), analytics team, sales. Not hundreds of clinicians. The service delivery component is targeted, not comprehensive.
Multiple payer contracts. Employer book growing through TPA partnerships. PMPM revenue on governance provides the stable base. Service delivery revenue layers margin on engaged high-risk populations. Total revenue reaches $100-125 million. EBITDA margins stabilize at 35-45% because the governance component scales on data and rules, not headcount.
Module expansion follows the data: autoimmune governance launches after maternity is proven. GI follows autoimmune. Each new module increases PMPM revenue and deepens the clinical data moat. The company that manages fertility, maternity, autoimmune, GI, and Rx as one integrated book has a dataset that no single-module competitor can match.
The historical record is clear. eviCore started as a utilization management delegator (pure governance) and expanded into care management capabilities over time. Evolent Health started as a population health governance platform and added direct clinical services through acquisitions (New Century Health for oncology pathways, Magellan Specialty Health including NIA for imaging governance with care management).22 Progyny started as a fertility benefit manager (governance-like) and is only now, in 2026, adding distribution through health plan channels.
The companies that started with service delivery and tried to add governance later had a harder path. Maven has 28 million covered lives and $268 million in ARR but still does not govern the women's health book for any payer. Pomelo delivers maternity care to 25 million lives but does not manage provider networks or Rx utilization at the population level. The consumer product creates member loyalty. It does not create governance authority.
Governance authority comes from managing the data. When you control the pathway decisions, the provider scorecards, and the utilization analytics, you control the operating system for the clinical domain. Adding services on top of that operating system is a natural extension. Trying to build the operating system after you have established yourself as a service delivery vendor is a different sell entirely.
| Phase | Revenue Source | PMPM Range | Margin Profile |
|---|---|---|---|
| 1: Pure Governance | PMPM on all female lives | $1.50-$3.00 | 65-70% gross, 40-50% EBITDA |
| 2: Governance + Data Services | PMPM + analytics/reporting upsells | $2.00-$3.50 | 60-65% gross, 35-45% EBITDA |
| 3: Hybrid | PMPM + service fees on managed lives | $3.00-$5.00 | 55-60% gross, 30-40% EBITDA |
| 4: National Scale | Blended governance + service + shared savings | $3.50-$5.00+ | 55-65% gross, 35-45% EBITDA |
The margin compression from Phase 1 to Phase 3 is deliberate. Service delivery requires clinical staff, which reduces gross margin per dollar of revenue. But the absolute margin per covered life increases because the PMPM rises faster than the cost of service delivery. A governance-only model at $1.50 PMPM and 70% gross margin generates $1.05 in gross profit per member per month. A hybrid model at $4.00 PMPM and 55% gross margin generates $2.20. The economics improve even as the margin percentage declines.
| Intervention | Annual Savings | Mechanism |
|---|---|---|
| NICU avoidance | $2,520,000 | High-risk pathway activation, remote monitoring triggers |
| Autoimmune flare prevention | $3,200,000 | Claims-based flare prediction, biologic management |
| C-section rate reduction (32.5% to 25%) | $176,000 | Provider performance transparency, midwifery steering |
| Biosimilar conversion | $1,400,000 | 60% net cost reduction per biologic switch23 |
| GI site-of-care steering | $680,000 | ASC redirection, endometriosis/IBS Dx correction |
| Lab optimization | $424,000 | Reference lab steering, redundancy elimination |
| Total | $8,400,000 |
At a midpoint PMPM of $2.25, the buyer's annual cost for this book is $2.7 million against $8.4 million in savings. A 3.1x ROI at full realization. At 60% realization (the conservative scenario), the savings are $5.04 million. Still a 1.9x return. The model does not require optimistic assumptions.
Founded through CareCore/MedSolutions merger. Reached $500M+ revenue and 100M+ covered lives within 3 years. Acquired by Express Scripts for $3.6B.24
Platform-only start. Added specialty governance through NCH (up to $217M, 2020) and Magellan Specialty Health including NIA (~$800M, 2022). Now manages ~80M lives with $2.55B revenue in 2024.25
Fertility benefit management. Employer-first GTM. Reached $1.29B revenue, 7.6M covered members, 600+ employer clients.26
Virtual maternity care. Payer-first GTM. 25M covered lives, $92M Series C at $1.7B valuation. Value-based contracts across 46 states.27
Any analysis of this market that ignores internal payer politics is incomplete. The buyer is not a monolith. It is a collection of stakeholders with different incentives, and the model you bring determines which stakeholders support you and which try to kill the deal.
| Stakeholder | Pure Governance | Service Delivery | Hybrid (Phased) |
|---|---|---|---|
| Chief Medical Officer | Cautiously positive. Retains medical policy authority. | Suspicious. External clinicians raise oversight questions. | Positive if positioned as augmentation. |
| OB/GYN Medical Director | Mixed. May feel territorial about "their" specialty. | Threatened. You have your own clinicians now. | Manageable. You solve their staffing gaps. |
| Care Management Nurses | Low threat. You make their work more targeted. | Directly threatened. Your navigators compete with theirs. | Moderate. Clear delineation required. |
| Actuaries | Strongly positive. They see unmanaged cost. | Positive but skeptical. Engagement-dependent ROI concerns. | Most positive. Both cost control and member impact. |
| Procurement | Familiar. PMPM is standard. | Complex. Clinical credentialing, licensure, malpractice. | Manageable. Governance base is simple. |
The hybrid model, approached through the governance-first sequence, has a structural political advantage that is counterintuitive. Pure governance walks in and says: "We are going to manage your women's health book." The internal medical director hears: "You are going to tell me how to run my specialty." The hybrid model, arriving through governance first, walks in and says: "We will govern the book using your protocols AND handle the 15% of cases your team does not have bandwidth for." The internal medical director hears: "You are going to solve my staffing problem."
The service component becomes the political lubricant for the governance sale. You give the internal team something they need (help with their hardest cases) in exchange for something you need (governance authority over the book). This is not manipulation. It is alignment of incentives. The payer gets better outcomes. The internal team gets support. The delegator gets data and revenue. When all three parties benefit, the contract renews.
The strongest version of any thesis is the one that has survived its own stress test. Seven open questions remain.
These are real risks. None of them is fatal. All of them have mitigation paths built into the phased model. But intellectual honesty requires naming them before the first contract is signed.
Women's health specialty spend is the fastest-growing benefit category, projected to reach $51-63 billion in addressable market by 2025 with a 14.2% CAGR.28 The governance-addressable portion of this market, B2B specialty management services, represents approximately $4-8B annually. McKinsey estimates that closing the women's health gap represents a $1 trillion global GDP opportunity.29 Investors have committed $2.6 billion to women's health startups in 2024 alone.30
The capital is flowing to apps, platforms, and virtual care. It is not flowing to governance infrastructure. The companies receiving that capital (Maven, Pomelo, Visana) are building consumer products that acquire members and deliver services. They are vendors. They compete with each other for the same employer contracts and health plan partnerships.
The governance layer sits underneath all of them. It manages the book regardless of which vendors the payer uses for member-facing services. A payer that contracts Maven for navigation and Progyny for fertility and Pomelo for maternity still needs someone to govern provider performance across the delivery network, manage cross-condition Rx utilization, enforce clinical pathway compliance, and report actuarial-grade savings attribution. That layer does not exist in women's health. It has existed in imaging for 30 years.
49 states plus DC now provide 12-month postpartum Medicaid coverage, up from a handful three years ago.31 Every state that extends coverage creates a new population that needs managed. Medicaid MCOs are the buyers, and they are buying management infrastructure because their internal teams cannot scale fast enough to absorb the expansion. The structural tailwind is regulatory, not speculative.
The governance-to-hybrid trajectory is not a theory. It is the operating history of the companies that built the specialty management category. NIA became Magellan Specialty Health. CareCore became eviCore and then Evernorth. New Century Health became Evolent's specialty engine. Accordant became CVS's complex disease management layer. Every one of them started by governing a clinical domain, proving savings, and expanding scope as the data matured and the relationships deepened.
The women's health governance seat is unoccupied. The question is not whether someone will occupy it. The question is who occupies it first.
[1] Magellan Health, NIA Impact Reports; Evolent Health acquisition of Magellan Specialty Health (~$800M), September 2022
[2] eviCore by Evernorth corporate overview, 2026. 5,000 employees, 500+ board-certified physicians, 1,200+ clinicians, 100M+ covered lives
[3] Evolent Health, "Evolent to Acquire New Century Health," press release, October 2020. Up to $217M (cash + stock + earn-out) for oncology/cardiology pathway management serving 3.5M lives
[4] National payer acquisition of AIM Specialty Health, 2014. Brought imaging management in-house to eliminate external PMPM fees
[5] Digital Health PMPM Pricing Frameworks, Quintuple Aim, 2025. Disease-specific management: $3-5 PMPM; population-wide: $0.30-0.50 PMPM
[6] CDC National Center for Health Statistics, Maternal Mortality Rates, 2024. 17.9 per 100,000 live births (down from 32.9 in 2021)
[7] CDC NCHS, Maternal Mortality by Race/Ethnicity, 2024. Black maternal mortality 3.2x white rate
[8] CDC Maternal Mortality Review Committees, Report on Pregnancy-Related Deaths, 2022. 84% preventable
[9] CDC National Vital Statistics Reports, 2025. C-section rate 32.5% (decade high); WHO recommended: 10-15%
[10] Health Care Cost Institute, Average NICU Costs, 2023
[11] American Autoimmune Related Diseases Association (AARDA). 80% of autoimmune patients are women
[12] AARDA Patient Survey. Average time to autoimmune diagnosis: 4.6 years
[13] Gastroenterology, "The Burden of Gastrointestinal Diseases in the US," 2024. $111.8B total spend
[14] CDC National Hospital Ambulatory Medical Care Survey. Women 41% more GI-related ED visits than men
[15] The Endometriosis Foundation of America; Ballard et al., BJOG 2006. IBS is the most common misdiagnosis, with diagnostic delays averaging 7-10 years
[16] Sacra, Maven Clinic Revenue and Valuation Estimates, 2025. $268M ARR, $1.7B valuation, 28M covered lives
[17] Rock Health Digital Health Consumer Adoption Survey, 2024. Typical digital health engagement: 3-8% of eligible population
[18] Progyny Inc., Q4 2025 Earnings Report. $1.29B revenue, 7.6M covered members, 600+ employer clients
[19] Progyny, "Progyny Expands Access with Fully Insured Supplemental Plan," press release, April 2026
[20] Fierce Healthcare, "Pomelo Care Raises $92M Series C at $1.7B Valuation," 2025. 25M covered lives across 46 states
[21] UnitedHealthcare "Healthy Pregnancy" (Optum); HumanaBeginnings; Cigna "Healthy Pregnancies, Healthy Babies"; payer-administered maternal health program descriptions and member materials
[22] Evolent Health 10-K filings. NCH acquired October 2020 (up to $217M). Magellan Specialty Health including NIA acquired from Centene September 2022 (~$800M). ~80M lives, $2.55B revenue FY2024
[23] IQVIA Biosimilar Cost Impact Analysis, 2024. 60% average net cost reduction per biologic-to-biosimilar switch
[24] Express Scripts acquisition of eviCore Healthcare, March 2017, approximately $3.6B. Cigna acquired Express Scripts December 2018 for $67B
[25] Evolent Health FY2024 earnings. $2.55B revenue, ~80M lives under management
[26] Progyny Q1 2026 earnings. $1.29B FY2024 revenue
[27] Pomelo Care Series C press release, 2025. $92M raised, $1.7B valuation, 25M lives, 46 states
[28] Mordor Intelligence, FemTech Market Size and CAGR Forecast, 2025. $51-63B market, 14.2% CAGR
[29] McKinsey & Company, "Closing the Women's Health Gap," 2024. $1T global GDP opportunity
[30] PitchBook / Rock Health, Women's Health Funding Report, 2024. $2.6B invested
[31] KFF, Medicaid Postpartum Coverage Extension Tracker, 2026. 49 states plus DC (only Arkansas without)